Galmed Pharmaceuticals (GLMD) Cash from Financing Activities (2013 - 2025)

Galmed Pharmaceuticals' Cash from Financing Activities history runs 12 years deep, the most recent figure standing at $1.2 million for Q4 2025.

• In Q4 2025, Cash from Financing Activities rose 165.18% year-over-year to $1.2 million; the TTM figure through Dec 2025 stood at $9.0 million (up 1461.59% YoY), while the FY2025 annual figure was $9.0 million, up 2.73% from the prior year.
• Cash from Financing Activities for Q4 2025 stood at $1.2 million, up from $289000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $17.4 million in Q1 2021, with the low at $130000.0 in Q1 2023.
• The 5-year median for Cash from Financing Activities is $818000.0 (2024), against an average of $3.4 million.
• The sharpest annual moves came in 2021 and 2022: Cash from Financing Activities soared 28372.13% in 2021, then tumbled 98.99% in 2022.
• Galmed Pharmaceuticals' Cash from Financing Activities stood at $17.4 million in 2021, then sank by 98.99% to $175000.0 in 2022, then retreated by 25.71% to $130000.0 in 2023, then surged by 244.62% to $448000.0 in 2024, then surged by 165.18% to $1.2 million in 2025.
• Business Quant data shows GLMD's Cash from Financing Activities at $1.2 million in Q4 2025, $289000.0 in Q3 2025, and $6.0 million in Q2 2025.